Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/27/2025

Seizure Management Guidelines

Introduction to Seizure Treatment

  • The American Academy of Neurology recommends carbamazepine as the first-line monotherapy for partial onset seizures in children and adults 1, 2
  • Standard antiepileptic drugs for partial seizures include carbamazepine, phenobarbital, phenytoin, and valproic acid, all offered as monotherapy 1, 2
  • In resource-limited settings, phenobarbital should be offered as the first option given acquisition costs, if availability can be assured 1, 2

Status Epilepticus Management

  • The American College of Emergency Physicians recommends IV lorazepam 4 mg at 2 mg/min as the first-line treatment for any actively seizing patient, with 65% efficacy in terminating status epilepticus 3
  • Benzodiazepines represent the strongest first-line treatment, with lorazepam demonstrating superior efficacy over diazepam (59.1% vs 42.6%) 3
  • IM midazolam or intranasal midazolam are alternatives when IV access is unavailable 3
  • Rectal diazepam should be administered when IV access is not available; IM diazepam is not recommended due to erratic absorption 2
  • Have airway equipment immediately available before administering lorazepam due to respiratory depression risk 3

Second-Line Treatment for Status Epilepticus

  • Valproate 20-30 mg/kg IV over 5-20 minutes should be administered as the preferred second-line agent, with 88% efficacy and 0% hypotension risk 3
  • Valproate demonstrates a superior safety profile compared to phenytoin/fosphenytoin (88% efficacy with 0% hypotension vs 84% efficacy with 12% hypotension) 3
  • Levetiracetam 30 mg/kg IV over 5 minutes is an excellent alternative with 68-73% efficacy and minimal cardiovascular effects 3, 4

Refractory Status Epilepticus Management

  • Midazolam infusion should be initiated as the first-choice anesthetic agent for refractory status epilepticus, with 0.15-0.20 mg/kg IV loading dose followed by 1 mg/kg/min continuous infusion 3
  • Midazolam demonstrates an 80% overall success rate with 30% hypotension risk, a superior safety profile compared to pentobarbital (77% hypotension) 3
  • Continuous EEG monitoring is essential at this stage to guide titration and detect ongoing electrical seizure activity 3

Special Populations

  • The American Academy of Neurology recommends seizures be controlled with antiepileptic drug monotherapy at the minimum effective dose, avoiding valproic acid and polytherapy in women of childbearing potential 1, 2
  • Folic acid should routinely be taken when on antiepileptic drugs 1, 2
  • Consider valproic acid or carbamazepine instead of phenytoin or phenobarbital due to lower risk of behavioral adverse effects in patients with intellectual disability 1, 2

Critical Monitoring and Management Principles

  • Antiepileptic drugs should not be routinely prescribed after a first unprovoked seizure 1, 2
  • Discontinuation of antiepileptic drug treatment should be considered after 2 seizure-free years, with the decision made after consideration of clinical, social, and personal factors 1, 2
  • Simultaneously search for and treat underlying causes during status epilepticus management, including hypoglycemia, hyponatremia, hypoxia, drug toxicity, CNS infection, stroke, and withdrawal syndromes 3
  • Continuous vital sign monitoring is essential, particularly respiratory status and blood pressure, with preparation to provide respiratory support 3